Herpes Simplex - Drug Pipeline Analysis and Market Forecasts to 2016

The global herpes simplex therapeutics market was worth approximately $2.9 billion in 2009. In 2001 the market was valued at approximately $1 billion and it grew at an approximate Compound Annual Growth Rate (CAGR) of 14% from 2001 to 2009. The global Herpes Simplex therapeutics market is expected to reach $6 billion by 2016, growing at a CAGR of 11.1%. The primary factor contributing to the increase in revenues over the forecast period is the increase in disease incidence. Presently, the therapeutic regimen for herpes simplex is dominated by a range of DNA polymerase inhibitors which include Zovirax, Famvir, Valtrex, Denavir and OTC (Over The Counter) products such as Abreva and Aviralex. This market is a significantly genericized market, with many brands across the seven geographies covered. Tablet prices range between $1 and $3 depending on the brand. The average annual cost of therapy for herpes simplex therapeutics ranges between $725 and $2,050 based on the treatment regimen (reduction or suppression therapy).